Login / Signup

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.

Sergio CedilloAlmudena González-DomínguezYoana Ivanova-MarkovaRafael López LópezSara López-Tarruella CoboJosé Alberto Peña Pedrosa
Published in: PharmacoEconomics - open (2024)
Olaparib as adjuvant treatment could be cost-effective in gBRCAm patients with early HER2neg BC in Spain.
Keyphrases
  • early breast cancer
  • early stage
  • smoking cessation
  • breast cancer risk